Neoadjuvant Zanidatamab Shows Early Efficacy, Tolerability in Early-Stage, Node-Negative, HER2+ Breast Cancer

Neoadjuvant zanidatamab monotherapy successfully reduced the incidence of residual disease and was well tolerated in treatment-naïve women with node negative, stage I HER2-positive breast cancer, potentially allowing patients to achieve pathologic complete responses in the absence of chemotherapy.

Related Keywords

Texas , United States , Vicente Valero , University Of Texas Md Anderson Cancer Center , Esmo Breast Cancer Annual Congress , Residual Cancer Burden , Cancer Center , Neoadjuvant Zanidatamab Monotherapy , Treatment Naïve Women With Node Negative , Tagei Her2 Positive Breast Cancer , Nct05035836 , The University Of Texas Md Anderson Cancer Center ,